Get the Stockscreener App
26.33
0.15%
-0.04
After Hours:
26.09
-0.24
-0.91%
Damora Therapeutics Inc stock is traded at $26.33, with a volume of 171.15K.
It is down -0.15% in the last 24 hours and up +0.00% over the past month.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
See More
Previous Close:
$26.37
Open:
$26.79
24h Volume:
171.15K
Relative Volume:
12.63
Market Cap:
$1.59B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$25.56
$27.60
1-Week Range:
$21.98
$27.60
52-Week Range:
$21.98
$27.60
Damora Therapeutics Inc Stock (DMRA) Company Profile
Name
Damora Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare DMRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
26.33 | 1.59B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Damora Therapeutics Inc Stock (DMRA) Latest News
Taxes of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Statistics – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Earnings and Revenue – NASDAQ:DMRA - TradingView
Total assets of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Galecto Changes Name to Damora Therapeutics, Advances mutCALR Antibody Pipeline for Blood Disorders and Secures $535M Funding 1 - Minichart
Galecto Rebrands as Damora Therapeutics with New Ticker - TipRanks
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders - Bitget
Galecto (GLTO) Rebrands to Damora Therapeutics, Plans Nasdaq Lis - GuruFocus
Galecto rebrands as Damora Therapeutics, begins Nasdaq trading - Investing.com
Damora Therapeutics holds $535M cash to target rare blood cancers - Stock Titan
Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Galecto announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Biotech brings in cancer drug veterans as it readies new antibody trial - Stock Titan
Mintz Advises Galecto, Inc. in its acquisition of Damora Therapeutics, Inc. and its concurrent $285 million private placement - Mintz
US: Galecto acquires Damora Tx and raises US$285m from Series C - Investors in Healthcare
Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally - Stocktwits
A Week Is A Long Time In Biotech, Just Ask Galecto - Citeline News & Insights
Galecto, Inc. (GLTO) Stock: Rockets After $284.9M Funding Boost and Strategic Damora Acquisition - parameter.io
Galecto Reports First Quarter 2025 Operating and Financial Results - marketscreener.com
GLTO Stock Price, News & Analysis - Stock Titan
Galecto to Participate in Upcoming Investor Conferences - marketscreener.com
Galecto Reports Third Quarter 2024 Financial Results - marketscreener.com
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - marketscreener.com
Galecto Announces Reverse Stock Split - marketscreener.com
Galecto to Present at Investor Conferences in September - marketscreener.com
Galecto Set to Join Russell Microcap® Index - marketscreener.com
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference - marketscreener.com
Galecto to Participate in SVB Securities Global Biopharma Conference - marketscreener.com
GALECTO, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - marketscreener.com
Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors - marketscreener.com
DMRA Stock Price and Chart — NASDAQ:DMRA - TradingView
Galecto Biotech AB Appoints Richard Marshall as Chief Medical Officer - marketscreener.com
Damora Therapeutics Inc Stock (DMRA) Financials Data
There is no financial data for Damora Therapeutics Inc (DMRA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Cap:
|
Volume (24h):